CHENGDU OLYMVAX BIOPHARMACEUTICALS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.79 CNY | -1.11% |
|
-2.10% | -38.04% |
| 05-16 | Olymvax Biopharma's Flu Vaccine Gets China Nod for Clinical Trials | MT |
| 04-25 | Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 51.53 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -38.04% | 554M | - | ||
| +2.52% | 92.1B | A- | ||
| -2.63% | 37.92B | A- | ||
| -12.37% | 32.97B | B- | ||
| +75.60% | 27.92B | A | ||
| -11.04% | 16.14B | C | ||
| -2.09% | 14.1B | B- | ||
| -11.93% | 11.66B | D+ | ||
| +177.66% | 10.29B | D | ||
| -50.94% | 9.99B | B |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- 688319 Stock
- Ratings Chengdu Olymvax Biopharmaceuticals Inc.